A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™

The burden of atherosclerotic cardiovascular disease contributes to a large proportion of morbidity and mortality, globally. Vaccination against atherosclerosis has been proposed for over 20 years targeting different mediators of atherothrombosis; however, these have not been adequately evaluated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Iversen, Patrick L., Kipshidze, Nicholas, Kipshidze, Nodar, Dangas, George, Ramacciotti, Eduardo, Kakabadze, Zurab, Fareed, Jawed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392828/
https://www.ncbi.nlm.nih.gov/pubmed/37534280
http://dx.doi.org/10.3389/fcvm.2023.1206541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392828/
https://www.ncbi.nlm.nih.gov/pubmed/37534280
http://dx.doi.org/10.3389/fcvm.2023.1206541

Ejemplares similares